Price Over Earnings Overview: TG Therapeutics

TG Therapeutics P/E Ratio Analysis in Relation to Industry Peers

TG Therapeutics has a better P/E ratio of 244.73 than the aggregate P/E ratio of 41.86 of the Biotechnology industry. Ideally, one might believe that TG Therapeutics Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued.

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.